RECKITT BENCKISER GROUP PLC

ISIN: GB00B24CGK77 WKN: B24CGK7 Asset Class: Stock



Company Profile

Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Johann A. Benckiser in 1823 and is headquartered in Slough, the United Kingdom.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20	22	20:	21
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	5,302,000,000		5,278,000,000		4,862,000,000	
Common stock capital		74,000,000		74,000,000		74,000,000
Fixed assets	21,834,000,000		23,464,000,000		22,084,000,000	
Equity capital of a company		8,469,000,000		9,483,000,000		7,453,000,000
Cash and cash equivalents	1,387,000,000		1,157,000,000		1,261,000,000	
Accrued liabilities		290,000,000		299,000,000		362,000,000
Other assets	-		-		-	
Current liabilities		8,338,000,000		8,341,000,000		8,088,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		10,329,000,000		10,918,000,000		11,405,000,000
Different income		-		-		-
Other liabilities		282,000,000		419,000,000		1,159,000,000
Total assets	27,136,000,000	27,136,000,000	28,742,000,000	28,742,000,000	26,946,000,000	26,946,000,000

Balance notes			

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	53,035	51,824	52,303
Equity ratio	31.29%	33.13%	27.86%
Debt-equity ratio	219.62%	201.82%	258.94%

Others			
	2023	2022	2021
Tax Expense Rate	31.36%	23.17%	80.93%

RECKITT BENCKISER GROUP PLC

ISIN: GB00B24CGK77 WKN: B24CGK7 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	14,607,000,000	14,453,000,000	13,234,000,000
Net income	1,634,000,000	2,337,000,000	-63,000,000
EBIT	3,111,154,800	3,824,808,000	-26,820,300
Operating income before taxes	2,401,000,000	3,069,000,000	-257,000,000
Cash Flow	2,636,000,000	2,397,000,000	1,697,000,000
Net interest income	-267,000,000	-211,000,000	-234,000,000
Research and development expenses	337,000,000	325,000,000	313,000,000
Income taxes	753,000,000	711,000,000	-208,000,000
Result from investments in subsidaries, associates and other	0	-2,000,000	-3,000,000
Revenues per employee	321,169	325,209	295,053

Chairman of Supervisory Board
Member of Supervisory Board

Members of Management Board		
Chairman of Managing Board		
Member of Executive Committee		